SGLT2 inhibitor empagliflozin could be a new treatment for children with type 2 diabetes: lancet

Published Date: 04 Mar 2023

United States: Empagliflozin could be a new treatment option for children and adolescents with type 2 diabetes, with phase 3 clinical trials showing...

Read Full News

Latest News

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

One in Four Teen Girls and Young Women at Risk for PMOS

Findings suggest young females should be assessed and, if at risk, monitored.

Novo Nordisk Flags Patient Data Breach From Some Clinical Trials in Cyberattack

Novo Nordisk said on Thursday it has identified a security incident in which certain information, including ⁠patient data from some clinical trials, was copied externally...

Todays Updates

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

Pain that interferes with daily functioning is associated with higher odds of frailty and its progression in adult survivors of childhood cancer.

The Growing Role of AI in Cancer Treatment

Cancer care is becoming too complex for any one clinician to track alone, making AI an increasingly valuable tool in modern oncology.

PSA Screening May Modestly Curb Prostate Cancer Deaths

New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

Capivasertib Wins Metastatic Prostate Cancer Approval

The CAPItello-281 trial reported a 19% improvement in radiographic progression-free survival.

Todays Updates

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

Pain that interferes with daily functioning is associated with higher odds of frailty and its progression in adult survivors of childhood cancer.

The Growing Role of AI in Cancer Treatment

Cancer care is becoming too complex for any one clinician to track alone, making AI an increasingly valuable tool in modern oncology.

PSA Screening May Modestly Curb Prostate Cancer Deaths

New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

Capivasertib Wins Metastatic Prostate Cancer Approval

The CAPItello-281 trial reported a 19% improvement in radiographic progression-free survival.

Latest News

The drug was previously approved for stage 2 T1D.

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

Findings suggest young females should be assessed and, if at risk, monitored.

Novo Nordisk said on Thursday it has identified a security incident in which certain information, including ⁠patient data from some clinical trials, was copied externally...

News All Time

Study Finds No Link Between Semaglutide and AMD Risk

Compared with other glucose-lowering drugs, semaglutide is not associated with the risk for neovascular age-related macular degeneration in adults with type 2 diabetes.

Can GLP-1s Curb Cancer Progression?

A real-world analysis links GLP-1s to substantially lower rates of metastatic progression in four cancers associated with obesity and/or diabetes — but experts urged caution to interpret the findings.

Skin Disorders in Transgender Patients: Treatment Tips

Dermatologists highlight the risks for acne, hair loss and unwanted hair, and melasma, as well as recent data on hidradenitis suppurativa.

Weekly and Monthly Berobenatide Show Weight, A1c Benefits

The long-acting GLP-1 drug had good overall tolerability with some GI bumps in weekly-to-monthly transition, while the A1c benefits raise hopes of a potential ‘game changer’ for T2D.

Roche Obesity Drug Helps Patients Shed 22.7% Of Weight in Mid-stage Trial

Roche said on Friday that patients lost 22.7% of their body weight in a mid-stage trial of its dual-acting experimental obesity ⁠drug, with more than a quarter of those who...

Beyond BMI: New Score Stratifies Obesity Risk

BMI, while useful, is insufficient to identify patients at the highest risk for obesity-related complications. A new tool may help clinicians better stratify risk and target treatment.

Wearables Generate the Data: What's Next for Chronic Care?

Wearable devices are moving beyond fitness tracking, providing clinicians with real-world data that may improve monitoring and continuity of care in chronic disease.

Tango Therapeutics' Pancreatic Cancer Drug Combo Shows Promise in Study

Tango Therapeutics said on Monday an experimental drug combination showed strong early results in a small study of patients ⁠with advanced pancreatic cancer and that it...

Liver-Directed Insulin: A New Way to Reduce Hypoglycemia?

Study findings suggest that a liver-targeted formulation of fast-acting insulin may reduce the risk for hypoglycemia in patients with type 1 diabetes.

Moving Beyond GLP-1s: Preclinical Acceleration, Innovation

Next-generation obesity therapeutics aim to counter weight rebound, decrease side effects, and support weight maintenance.

Dual Incretin Agonist Survodutide Benefits Liver in Phase 3

The glucagon receptor/GLP-1 receptor dual agonist reduces weight, visceral fat, and liver fat.

From Taboo to Test: Can Menstrual Blood Aid Diagnosis?

Emerging research suggests that menstrual blood may provide valuable diagnostic and biological insights, with potential applications in cancer screening and endometriosis detection.

Do Corticosteroids Really Raise Gestational Diabetes Risk?

Emerging research says the steroids aren’t a major driver of gestational diabetes, but impacts vary depending on the patient.

No Increased Retinopathy Risk Seen With Tirzepatide

No changes in diabetic retinopathy status occurred in high-risk people with type 2 diabetes taking tirzepatide when compared with dulaglutide.

Petrelintide Tolerability Could Improve on GLP-1 Challenges

The amylin analog petrelintide reduces body weight with 'placebo-like' tolerability, a phase 2 trial shows.

GLP-1 QOL Benefits Greatest for Those With Obesity Plus T2D

Patients with obesity and type 2 diabetes have more favorable QOL outcomes taking a GLP-1 than those with either condition alone or with multiple comorbidities.

Recommended News For You

Enhanced CAR T cell therapy offers new strategy for lymphoma

Worse Outcomes After Esophagectomy at Private Equity-Owned Hospitals

Durvalumab Wins FDA Approval in Limited-Stage SCLC

Rural residents continue to have higher odds of skin cancer, study finds

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.

Lung cancer screening adherence rates decline annually after baseline screening

Recommended Articles For You

Unlocking the Mystery of Ovarian Cancer Staging 

Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy 

Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier 

Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Promising Results With Epcoritamab Monotherapy in Relapsed/Refractory CLL

2.

Immunotherapy and targeted radiation shrink liver tumors, enabling surgery

3.

Childhood cancer survivors face new health problems later in life, study shows

4.

Coffee, Tea Tied to Lower Risk of Head and Neck Cancer

5.

Routine breast cancer screening can bring better outcomes for patients

1.

Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care

2.

Unraveling the Mystery of Non-Caseating Granulomas: A Comprehensive Guide

3.

Precision Oncology: Tailoring Cancer Treatment for the Individual

4.

Immunotherapy Breakthroughs: Transforming Cancer Care Across All Oncology Fields

5.

Strategic Practices in Oncology for Specialists

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

3.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

5.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot